Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Serina Therapeutics ( (SER) ) just unveiled an update.
Serina Therapeutics has made a significant update to its 2024 Equity Incentive Plan, which was approved by the company’s stockholders at the 2024 Annual Meeting. The amendment increases the number of shares of common stock reserved for issuance by 950,000 shares and includes an automatic annual increase mechanism starting from the 2026 fiscal year up to 2034. This move indicates a strategic effort to enhance employee incentives and potentially attract new talent, supporting the company’s growth and operational objectives. Additionally, the meeting saw the election of three directors and the ratification of the appointment of Frazier & Deeter, LLC as the company’s auditors, reflecting stable governance and financial oversight.
More about Serina Therapeutics
YTD Price Performance: -69.35%
Average Trading Volume: 24,001
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $42.59M
See more data about SER stock on TipRanks’ Stock Analysis page.
